Finest Penny Shares To Purchase On Robinhood Now? 12 To Watch This Week

12 min learn

This story initially appeared on PennyStocks

Biotech Penny Shares Stay A Focus Heading Into Q3 2021

Penny shares are well-known for his or her excessive threat and excessive reward potential. There aren’t many locations the place you should buy into an early-stage firm, see shares rise 100% or extra, and take revenue all inside a single day or week. Merchants search catalysts for potential strikes then speculate on that catalyst forward of time, in lots of circumstances. This may be one thing like upcoming earnings outcomes, pending retail information, or, within the case of biotech shares, upcoming FDA choices, or trial information.

In comparison with firms within the supplies sector, retail, and even vitality, biotech firms are likely to pre-announce information. What I imply by that is that you just’ll steadily see these firms launch information of once they count on to report an occasion. Once more this may be an FDA choice, trial information, “extra trial information,” an business presentation, or one thing else. It’s one of many distinctive issues about biotech that pulls momentum hunters.

[Read More] 9 Sizzling Penny Shares To Watch Proper Now, Analyst Targets Up To 290%

Even when the information is dangerous on the announcement day, hypothesis can set off a bullish pattern main as much as the official date. That is the place the well-known saying, “purchase the rumor, promote the information,” takes on a vivid gentle. It’s additionally the place we see the “Robinhood merchants” turning into a supply of hypothesis. Because it is without doubt one of the most generally used platforms amongst retail merchants, the main focus, in terms of penny shares, is on Nasdaq & NYSE-listed firms. The reason being easy: Robinhood and apps like Webull usually prohibit entry to different penny shares like these buying and selling on the OTC.

Biotech Penny Shares To Watch This Week

Now we’ve bought our base case laid out. One thing to contemplate subsequent is timing. Corporations will usually do certainly one of two issues. They’ll both announce a selected date or convention to current at, or they’ll focus on a broader interval. This could possibly be one thing like “the tip of X month” or “within the X quarter or half of the yr.”

Proper now, we’re approaching a doubtlessly lively interval of the yr. Not solely is it the tip of the month, however it’s additionally the tip of the quarter and the primary half of the yr. It’s time to name in all these updates stating “by the tip of June, Q2, H1 or earlier than Q3, H2 2021.” With this in thoughts, listed below are 12 biotech penny shares to look at this week with beforehand introduced occasion dates to remember.

Word: That These Are Tentative Dates & Might Change At The Corporations’ Route

So let’s dive in and see precisely what may be forward contemplating we’re in “Late June,” the twenty ninth is Tuesday, and Q2 2021 ends this week.

Robinhoood Penny Shares To Watch This Week #1: Hepion Prescribed drugs (NASDAQ: HEPA)

Hepion Prescribed drugs focuses on growing therapy candidates for non-alcoholic steatohepatitis or NASH. Its CRV431 – AMBITION NASH examine accomplished enrollment earlier this quarter and is the middle level of focus proper now. Hepion’s June investor deck* reveals that this NASH medical program anticipates Section 2a information in “Q2” 2021. With the enrollment completion introduced in early Might, it’s necessary to maintain the examine’s timeline in thoughts. In a Might sixth replace, Hepion stated, “After completion of 28 days dosing with both CRV431 or placebo, examine topics might be monitored for an extra 14 day interval.”

2. Daré Bioscience, Inc. (NASDAQ: DARE)

Shares of Daré have climbed over the previous week on above-average quantity. This may increasingly have been due, partly, to a latest firm presentation on the 2021 BIO Digital occasions. President and CEO Sabrina Martucci Johnson gave an outline of the corporate’s portfolio at this occasion. One among its merchandise, DARE-BV1, could possibly be the middle of focus heading into the tip of the quarter. That’s as a result of Daré beforehand introduced plans to submit a New Drug Utility (NDA) to the U.S. FDA this quarter.

[Read More] Tech Penny Shares Are in Focus, Right here’s Why And seven to Watch

DARE-BV1 is a hydrogel used for treating bacterial vaginosis. Earlier information has already proven that the therapy delivered “statistically vital efficacy” within the intent-to-treat inhabitants. . It additionally confirmed improved medical remedy charges in comparison with present branded merchandise. Moreover, in line with the corporate’s March thirtieth, 2021 PR, “Quick monitor and Certified Infectious Illness Product (QIDP) designations enable for a precedence overview request on the time of NDA submission, which, if granted by the FDA, might result in a 2021 PDUFA aim date.”

3. Palisade Bio, Inc. (NASDAQ: PALI)

You may know Palisade Bio by its former identify, Seneca Biopharma (f/ok/a SNCA), or a non-public firm, Main BioSciences. The 2 joined forces earlier this yr in a merger that resulted within the formation of this new firm. Palisade focuses on therapies for gastrointestinal problems stemming from post-op digestive enzyme harm. Earlier this month, the corporate introduced {that a} Section 2 examine of its LB1148 therapy candidate expects preliminary top-line information “by the tip” of the second quarter. This therapy is the corporate’s candidate for post-surgical GI problems. Heading into the week, the countdown begins to see if Palisade delivers on the beforehand introduced milestone. Total, PALI inventory doesn’t appear to have skilled any uncommon market exercise to date.

4. Ocuphire Pharma, Inc. (NASDAQ: OCUP)

In Might, Ocuphire introduced a possible milestone interval for traders to notice. The corporate focuses on ophthalmic pharmaceutical improvement. Particularly, Ocuphire has been constructing upon efforts to advance its Nyxol candidate in treating a number of indications for eye care.

Learn Extra

The corporate has constructed an property of patent and patent functions across the therapy. This month, specifically, could possibly be an necessary one for the corporate. Ocuphire beforehand introduced that top-line information from its VEGA-1 Section 2 presbyopia trial is predicted by the tip of June.

biotech penny stocks to watch this week Kintara Therapeutics KTRA stock chart

5. Kintara Therapeutics, Inc. (NASDAQ: KTRA)

One other one of many biotech penny shares with pending information to report is Kintara. Earlier this quarter, the corporate introduced that it accomplished enrollment of the recurrent arm of a Section 2 medical examine of its VAL-083 at MD Anderson Most cancers Middle. That is the corporate’s candidate for treating glioblastoma multiforme. This present examine is anticipated to report top-line outcomes this quarter. VAL-083 has beforehand proven medical exercise in opposition to a number of cancers. These embrace central nervous system, ovarian, and different stable tumors (e.g., NSCLC, bladder most cancers, head, and neck) in U.S. medical trials sponsored by the Nationwide Most cancers Institute.

Robinhoood Penny Shares To Watch This Week #6:Diffusion Prescribed drugs Inc. (NASDAQ: DFFN)

Diffusion Pharma focuses on methods to ship oxygen to the physique in areas that want it most. Its trans sodium crocetinate (TSC) is being developed for peripheral tissue oxygenation to forestall hyperoxia. Heading into this week, particulars from a Might tenth launch carry TSC into focus. The corporate introduced that information from a Section 1 examine can be accomplished and introduced by the tip of the second quarter. Diffusion trial is evaluating the consequences of TSC on peripheral tissue oxygenation utilizing a transcutaneous oxygen monitoring gadget. Final week, CEO Robert Cobuzzi, Jr., Ph.D., offered on the Life Sciences Investor Discussion board on June twenty fourth.

7. MediWound Ltd. (NASDAQ: MDWD) & Vericel Company (NASDAQ: VCEL)

Late final yr, the FDA accepted Vericel’s Biologics License Utility submission for NexoBrid. That is the corporate’s candidate for eschar removing in adults with deep partial-thickness/ full-thickness thermal burns. “The FDA’s acceptance of the NexoBrid BLA for overview represents one other necessary milestone towards our aim of offering a brand new commonplace of take care of eschar removing in sufferers with extreme burns,” stated Nick Colangelo, President, and CEO of Vericel Company (NASDAQ: VCEL).

[Read More] 7 Penny Shares On Robinhood To Watch In June 2021

The FDA assigned a Prescription Drug Consumer Price Act (PDUFA) goal date of June twenty ninth. Contemplating that that is developing on Tuesday, VCEL inventory might have a doubtlessly unstable week forward, relying on the end result. How is MediWound tied into this? Vericel holds an unique license from MediWound Ltd. for North American rights to NexoBrid®.

biotech penny stocks to watch this week MediWound Ltd MDWD stock chart

8. AzurRx BioPharma, Inc. (NASDAQ: AZRX)

One other firm specializing in gastrointestinal ailments is AzurRx Biopharma. The corporate’s MS1819, specifically, is being developed and evaluated in a Section 1 trial for treating extreme exocrine pancreatic insufficiency in cystic fibrosis sufferers. Interim information from the primary 18 sufferers within the 20 affected person trial confirmed significant interim information already. In line with the corporate, the therapy together with the present commonplace of care confirmed potential to assist 25-30% of refractory cystic fibrosis sufferers unable to realize enough diet. Full top-line outcomes from all 20 sufferers are anticipated to be reported this quarter. So heading into the week, the countdown has begun.

9. Cerecor Inc. (NASDAQ: CERC)

Cerecor is an organization specializing in growing therapy candidates for immunology, oncology, and uncommon ailments. This week, its CERC-002 therapy might catch the attention of the market. That is Cerecor’s Crohn’s illness therapy. It has already demonstrated enchancment in a main endpoint of a Section 2 COVID-19 acute respiratory misery syndrome trial. So far as the week is anxious, the corporate’s June investor deck** confirmed that preliminary information from extreme pediatric-onset Crohn’s is predicted in Q2.

biotech penny stocks to watch this week Cerecor Inc. CERC stock chart

10. Optinose (NASDAQ: OPTN)

This has been a comparatively flat yr for OPTN inventory. Nonetheless, the approaching week could possibly be an necessary one for these with Optinose on their watch listing. The corporate focuses on ear, nostril, throat, and allergy therapies. It has a pipeline of various property, all concentrating on completely different therapy sorts. Proper now, its OPN-019 could possibly be the extra quick focus.

Learn Extra

That is Optinose’s candidate for treating those that’ve examined constructive for SARS-CoV-2, are just lately contaminated, and who’ve delicate or no signs. In March, the corporate introduced the plan to conduct this proof of idea examine. It was designed to guage the magnitude and length of viral load discount after a single dose for OPN-019. Whereas regulatory approval was pending on the time of a Might replace, the corporate stated it anticipated topline information this quarter.

11. NeuroBo Prescribed drugs, Inc. (NASDAQ: NRBO)

NeuroBo’s ANA001 therapy could possibly be a degree of focus this week. The corporate is designing it as a possible therapy for reasonable to extreme COVID-19. Proper now, NeuroBo is advancing a 60-patient Section 2/3 medical trial.

In a late-Might replace, Richard J. Kang, Ph.D., President and Chief Government Officer of NeuroBo, defined, “We stay on monitor to report the information monitoring committee security outcomes of this examine and pharmacokinetic (PK) information from the Section 1 within the second quarter. With a view to improve enrollment within the Section 2/3 examine, we’re within the means of increasing to websites within the U.S. the place the variety of COVID-19 circumstances are rising and together with medical websites in nations abroad the place COVID-19 is rising, and vaccinations are effectively behind the U.S. As well as, we count on to report preclinical in vitro information demonstrating Gemcabene’s potential to deal with COVID-19 variants alone and together with ANA001.”

12. Lineage Cell Therapeutics, Inc. (NYSE: LCTX)

Lineage has been a prime performer for the higher a part of the final yr. Since final summer season, LCTX shares have climbed from below $0.80 to over $3 earlier this yr. Now, heading into the brand new week, the penny inventory is again above $3 with the corporate anticipated to launch updates someday “in Q2.” In gentle of the present timing, there aren’t many days left for this to be executed. Right here’s the “skinny” on why I say this.

Final month, Lineage gave its Q1 2021 replace. Its lead drug candidate, OpRegen. Lineage has this below improvement for treating Dry Age-related Macular degeneration – AMD – with Geographic Atrophy – GA. Earlier medical information has already proven that OpRegen is “suggestive of clinically significant advantages,” most notably in early-stage illness sufferers. Particularly, final month, the corporate introduced that it will be presenting extra interim information from its Section 1/2a examine “anticipated” in Q2.

biotech penny stocks to watch this week Lineage Cell Therapeutics LCTX stock chart

Penny Shares To Purchase Or Keep away from Proper Now?

Clearly, it’s necessary to do your analysis in terms of biotech shares. Not solely is that this to organize for any upcoming occasions however to additionally not get blindsided both. For example, for those who have a look at simply the previous couple of weeks of knowledge from an organization and see promise, you may miss a few of the data reported way back to months or years in the past about what’s to come back.

Learn Extra

I talked about Vericel earlier. It gave its June 2021 PDUFA goal date in September of 2020. Issues like this aren’t unusual both. For those who don’t know that there’s an necessary occasion deliberate, it could possibly be dangerous if issues come out lower than favorable. So you possibly can see how not understanding an replace from to date again might pose a possible threat. On the identical time, it may also be a contented shock if the information is nice. On the finish of the day, nevertheless, it’s important to know the company panorama. After studying this text, nevertheless, you’ll have extra data to remember heading into the ultimate days of the month, quarter, and half.

best penny stocks to watch before the market opens

Finish Notes:

  • *https://hepionpharma. com/wp-content/uploads/2021/06/Company-deck-June-2021-FINAL. pdf
  • **https://d1io3yog0oux5.cloudfront. internet/_c9dce8b9ea83152afd4224eb4cb0a98f/cerecor/db/282/1110/pdf/Cerecor+Jefferies+Digital+Healthcare+Convention+2JUNE2021. pdf

Source link